Skip to main content
SpringerLink
Log in

Daclizumab

  • Chapter
  • First Online:
Adverse Events with Biomedicines

  • 1224 Accesses

Abstract

Daclizumab (Zenapax®, Roche) is a humanized murine monoclonal IgG1k antibody specifically binding to the high affinity interleukin-2 (IL-2R) expressed on human lymphocytes. At the end of 2009 its production was discontinued and the supply was announced to last up to 2011. However, some trials are exploring new indications, and long-term observations are still collecting data, which are relevant for safety evaluation of chronic exposures to this class of biomedicines.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 169.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 219.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD 219.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

References

  1. Daclizumab (Zenapax®) BLA 97-0736 FDA Clinical Review 1997

    Google Scholar 

  2. Daclizumab (Zenapax®) BLA 97-0736 FDA Safety Review 1997

    Google Scholar 

  3. Carswell C, Plosker GL, Wagstaff AJ (2001) Daclizumab. A review of its use in the management of organ transplantation. BioDrugs 15:745–773

    Article  PubMed  CAS  Google Scholar 

  4. Zenapax® (Daclizumab) Label, Hofmann-La Roche, US 2005

    Google Scholar 

  5. Zenapax® (Daclizumab) Product Monograph, Hoffmann-La Roche, Canada 2007

    Google Scholar 

  6. Daclizumab (Zenapax®) EPAR WC50007604 Product Information Annex I, EMEA 2008

    Google Scholar 

  7. Binder M, Vögtle FN, Michelfelder S et al (2007) Identification of their epitope reveals the structural basis for the mechanism of action of the immunosuppressive antibodies Basiliximab and Daclizumab. Cancer Res 67:3518–3523

    Article  PubMed  CAS  Google Scholar 

  8. Bielkova B (2012) Daclizumab therapy for Multiple Sclerosis. Neurotherapeutics. doi:10.1007/s13311-012-0147-4

    Google Scholar 

  9. Gold R, Giovannoni G, Selmaj K et al (2013) Daclizumab high-yield process in relapsing-remitting multiple sclerosis (SELECT): a randomized, double-blind placebo-controlled trial. Lancet. doi:10.1016/S0140-6736(12)62190-4

    Google Scholar 

  10. Daclizumab (Zenapax®) BLA 97-0736 FDA Non-clinical pharmacology and toxicology review 1997

    Google Scholar 

  11. FDA Safety information letter. Medwatch, August 2003

    Google Scholar 

  12. Birgerson LE (2009) Important drug information. Roche, US Medical Affairs

    Google Scholar 

  13. Emre S, Gondolesi G, Polat K et al (2001) Use of daclizumab as initial immunosuppression in liver transplant recipients with impaired renal function. Liver Transpl 7:220–225

    Article  PubMed  CAS  Google Scholar 

  14. Yoshida EM, Marotta PJ, Greig PD et al (2005) Evaluation of renal function in liver transplant recipients receiving daclizumab (Zenapax), Mycophenolate Mofetil regimen: a multicenter randomized clinical trial. Liver Transpl 9:1064–1072

    Article  Google Scholar 

  15. Otero A, Varo E, Ortiz de Urbina J et al (2009) A prospective randomized open study in liver transplant recipients: Daclizumab, Mycophenolate Mofetil, and Tacrolimus versus Tacrolimus and Steroids. Liver Transpl 15:1542–1552

    Google Scholar 

  16. Neumann U, Samuel D, Trunečka P et al (2012) A randomized multicenter study comparing a Tacrolimus-based protocol with and without Steroids in HCV-positive liver allograft recipients. J Transpl. doi:10.1155/2012/894215

    Google Scholar 

  17. Klintmalm GB, Davis GL, Teperman L et al (2011) A randomized, multicenter study comparing steroid-free immunosuppression and standard immunosuppression for liver transplant recipients with chronic hepatitis C. Liver Transpl 17:1394–1403

    Article  PubMed  Google Scholar 

  18. Chin C, Pittson S, Luikart H et al (2005) Induction therapy for pediatric heart and adult transplantation: comparison between OKT3 and daclizumab. Transplantation 80:477–481

    Article  PubMed  CAS  Google Scholar 

  19. Coehlo T, Tredger M, Dhawan A et al (2012) Current status of immunosuppressive agents for solid organ transplantation in children. Ped. Transpl 16:106–122

    Article  Google Scholar 

  20. Nussenblatt RB, Peterson JS, Foster S et al (2005) Initial evaluation of subcutaneous daclizumab treatments for noninfectious uveitis. Ophthalmology 112:764–770

    Article  PubMed  Google Scholar 

  21. Larson T, Nussenblatt RB and Nida Sen H (2011) Emerging drugs for uveitis. Expert Opin Emerg Drugs 16:309–322

    Google Scholar 

  22. Yeh S, Wroblewski K, Buggage R et al (2008) High-dose humanized anti-IL-2 receptor alpha antibody (daclizumab) for the treatment of active, noninfectious uveitis. J Autoimmun 31:91–97

    Article  PubMed  CAS  Google Scholar 

  23. Pasadhika S, Suhler E, Cunningham ET (2012) Biologic therapy for posterior uveitis and panuveitis. Retina Today 4:74–79

    Google Scholar 

  24. Wroblewski K, Nida Sen H, Yeh S et al (2011) Long-term daclizumab therapy for the treatment of noninfectious ocular inflammatory diseases. Can J Ophthalmol 46:322328

    Google Scholar 

  25. Rojas MA, Carlson NG, Miller TL et al (2009) Long-term daclizumab therapy in relapsing-remitting multiple sclerosis. Ther Adv Neurol Disord 2:291–297

    Article  PubMed  Google Scholar 

  26. Shippling S, Martin R (2008) Spotlight on anti-CD25: Daclizumab in MS. Intern MS J 15:94–98

    Google Scholar 

  27. Martin R (2012) Anti-CD25 (daclizumab) monoclonal antibody therapy in relapsing-remitting multiple sclerosis. Clin Immunol 142:9–14

    Article  PubMed  CAS  Google Scholar 

  28. Giovannoni G, Gold R, Selmaj K et al (2011) A randomized, double-blind, placebo-controlled study to evaluate the safety and efficacy of daclizumab HYP monotherapy in relapsing-remitting multiple sclerosis: primary results of the SELECT trial. Multiple Sclerosis Journal ,Ectrims, Amsterdam ; 17: S507–S524

    Google Scholar 

  29. Giovannoni G, Gold R, Selmaj K et al (2012) Primary results of the SELECTION trial of daclizumab HYP in relapsing multiple sclerosis. Ectrims, Lyon

    Google Scholar 

  30. Liu J, Wang L, Zhan SY et al (2012) Daclizumab for relapsing remitting multiple sclerosis (review)- The Cochrane Library, issue 4 (www.thecochranelibrary.com)

  31. Jiang W, Chai NR, Maric D et al (2011) Unexpected role for granzyme K in CD56bright NK cell-mediate immunoregulation of multiple sclerosis. J Immunol 187:781–790

    Article  PubMed  CAS  Google Scholar 

  32. Perry JSA, Han S, Xu Q et al (2012) Inhibition of LTi cell development by CD25 blockade is associated with decreased intrathecal inflammation in multiple sclerosis. Sci Transl Med 4:145ra106 doi: 10.1126/scitranslmed.3004140

Download references

Author information

Authors and Affiliations

  1. University of Verona, Verona, Italy

    Giuseppe Tridente

Authors
  1. Giuseppe Tridente
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Giuseppe Tridente .

Rights and permissions

Reprints and permissions

Copyright information

© 2014 Springer-Verlag Italia

About this chapter

Cite this chapter

Tridente, G. (2014). Daclizumab. In: Adverse Events with Biomedicines. Springer, Milano. https://doi.org/10.1007/978-88-470-5313-7_16

Download citation

Publish with us

Policies and ethics

Search

Navigation